Scottish company Ingenza, a leader in the application of industrial biotechnology and synthetic biology, has become a stakeholder in Amprologix, a spin-out company from the University of Plymouth. Launched in collaboration with Frontier IP – a specialist in commercialising university intellectual property and a stakeholder in the new company – Amprologix aims to develop and bring to market novel antimicrobials to tackle antibiotic resistance, a global threat to human health.
UK biotech company Ingenza has joined forces with leading universities and industrial partners to participate in the ConBioChem collaboration, a translational project focused on the development of novel platform technologies for the continuous bio-production of commodity chemicals.
“The UK cannot solve the problem on its own, and we will need to collaborate with foreign governments and companies if we are to truly tackle the crisis ahead.” To say it referring to Brexit – in this exclusive interview with Il Bioeconomista – is Jaymin Amin, COO at Ingenza, the spin-out from the University of Edinburgh founded in 2002, which is today one of the most dynamic European industrial biotech company. With Amin we talk about industrial biotechnology and bioeconomy in Scotland.
Interview by Mario Bonaccorso